OverviewSuggest Edit

Seres Therapeutics is a microbiome therapeutics platform company which engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology to treat multiply recurrent Clostridium difficile infection. The Company also develops a number of other product candidates for treatment of various diseases, including ulcerative colitis, Clostridium difficile infection, inflammatory bowel disease, etc.

TypePublic
Founded2010
HQCambridge, US
Websiteserestherapeutics.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)108(-25%)
Job Openings15
Revenue (FY, 2019)$34.5 M(+23%)
Share Price (Sept 2020)$26.5
Cybersecurity ratingBMore

Key People/Management at Seres Therapeutics

Eric Shaff

Eric Shaff

President, Chief Executive Officer & Director
John Aunins

John Aunins

Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
Kelly M. Brady

Kelly M. Brady

Vice President, Clinical Operations
Stephen Berenson

Stephen Berenson

Chairman
Gloria G. Cosgrove

Gloria G. Cosgrove

Vice President, Quality Systems
Grégory Behar

Grégory Behar

Director
Show more

Seres Therapeutics Office Locations

Seres Therapeutics has an office in Cambridge
Cambridge, US (HQ)
200 Sidney St
Show all (1)

Seres Therapeutics Financials and Metrics

Seres Therapeutics Revenue

Seres Therapeutics's revenue was reported to be $34.51 m in FY, 2019
USD

Revenue (Q2, 2020)

6.0m

Net income (Q2, 2020)

(20.7m)

EBIT (Q2, 2020)

(20.5m)

Market capitalization (22-Sept-2020)

2.4b

Closing stock price (22-Sept-2020)

26.5

Cash (30-Jun-2020)

61.5m

EV

2.3b
Seres Therapeutics's current market capitalization is $2.4 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

21.8m32.1m28.3m34.5m

General and administrative expense

16.8m32.6m34.0m32.6m24.7m

R&D expense

38.1m82.0m89.5m96.0m80.1m

Operating expense total

54.9m114.6m123.5m128.6m106.4m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.7m3.0m13.0m3.0m3.0m23.0m4.0m4.6m9.1m7.3m12.5m7.0m8.2m6.0m

General and administrative expense

3.6m4.7m7.2m9.0m8.0m8.8m8.4m8.1m8.8m8.7m7.6m7.5m5.6m5.9m6.1m6.5m

R&D expense

8.8m9.9m15.4m22.2m24.1m20.1m23.1m22.2m23.5m24.1m23.7m22.9m17.9m18.3m21.7m20.1m

Operating expense total

12.3m14.6m22.6m31.1m32.1m28.9m31.4m30.3m32.2m32.7m31.3m31.9m23.5m24.2m27.9m26.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

73.9m54.5m36.1m85.8m65.1m

Accounts Receivable

1.8m

Prepaid Expenses

5.1m6.8m3.6m

Inventories

2.5m5.1m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

36.3m69.7m193.2m59.8m55.6m41.9m33.6m46.0m47.2m58.0m55.7m53.6m102.2m49.3m54.9m61.5m

Accounts Receivable

6.7m1.6m1.7m2.1m2.9m

Prepaid Expenses

2.3m3.0m3.6m5.2m5.1m5.2m4.8m5.3m4.3m5.5m6.6m7.5m5.2m4.1m3.4m5.8m

Current Assets

94.1m222.4m306.8m217.1m208.4m192.3m176.1m176.6m126.5m101.5m79.4m67.8m109.0m89.6m80.6m72.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.8m)(91.6m)(89.4m)(98.9m)(70.3m)

Depreciation and Amortization

728.0k4.2m7.3m7.9m7.6m

Inventories

(2.5m)(2.6m)

Accounts Payable

2.7m3.6m(856.0k)(353.0k)(1.5m)
USDQ2, 2015

Financial Leverage

1.1 x
Show all financial metrics

Seres Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Seres Therapeutics Online and Social Media Presence

Embed Graph

Seres Therapeutics News and Updates

Thinking about buying stock in Trevena Inc, Seres Therapeutics, CleanSpark Inc, Lipocine Inc, or Tilray Inc?

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, MCRB, CLSK, LPCN, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections

Shares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), or an infection of the colon. Trading vo…

Human Microbiome World Markets to 2023, Featuring Chr. Hansen, Enterome Bioscience, Seres Therapeutics, and Viome

DUBLIN, Nov. 25, 2019 /PRNewswire/ -- The "Growth Opportunities in Human Microbiome Market, Forecast to 2023" report has been added to ResearchAndMarkets.com's offering. This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive...

BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc

* Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc As Of April 10, 2018 - SEC Filing Source text (https://bit.ly/2GSzKlq) Further company coverage: (Reuters.Briefs@thomsonreuters.com…

Seres Therapeutics Blogs

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

– Topline data from SER-109 Phase 3 study in recurrent C. difficile infection expected in August 2020 ; Potential to be the single pivotal study supporting FDA product registration – – Company continues to advance multiple additional clinical-stage microbiome therapeutic programs, including

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

– Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres’ microbiome therapeutic pipeline – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 22, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young

Seres Therapeutics, Inc. at the Goldman Sachs Healthcare Conference

Seres Therapeutics, Inc. at the Goldman Sachs Healthcare Conference John.Bissaillo… Tue, 06/09/2020 - 10:13 Seres Therapeutics, Inc. at the Goldman Sachs Healthcare Conference Display "add to calendar" true Event Type Conference Presentation …

Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41 st Annual Global Virtual Healthcare Conference on Tuesday, June 9 th at 2:10 p.m. ET .

Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET . A live audio webcast of the presentation will be available

Seres Therapeutics, Inc. at the Jefferies 2020 Healthcare Conference

Seres Therapeutics, Inc. at the Jefferies 2020 Healthcare Conference John.Bissaillo… Thu, 05/21/2020 - 13:31 Seres Therapeutics, Inc. at the Jefferies 2020 Healthcare Conference Display "add to calendar" true Event Type Conference Presentation …
Show more

Seres Therapeutics Frequently Asked Questions

  • When was Seres Therapeutics founded?

    Seres Therapeutics was founded in 2010.

  • Who are Seres Therapeutics key executives?

    Seres Therapeutics's key executives are Eric Shaff, John Aunins and Kelly M. Brady.

  • How many employees does Seres Therapeutics have?

    Seres Therapeutics has 108 employees.

  • What is Seres Therapeutics revenue?

    Latest Seres Therapeutics annual revenue is $34.5 m.

  • What is Seres Therapeutics revenue per employee?

    Latest Seres Therapeutics revenue per employee is $319.5 k.

  • Who are Seres Therapeutics competitors?

    Competitors of Seres Therapeutics include Ventus Therapeutics, Kangstem Biotech and Corestem.

  • Where is Seres Therapeutics headquarters?

    Seres Therapeutics headquarters is located at 200 Sidney St, Cambridge.

  • Where are Seres Therapeutics offices?

    Seres Therapeutics has an office in Cambridge.

  • How many offices does Seres Therapeutics have?

    Seres Therapeutics has 1 office.